Ranbaxy ties up with US firm

Pharma major Ranbaxy Laboratories has entered into a strategic partnership with US-based Invagen Pharmaceuticals Inc for marketing Zonisamide capsules, which are used for the treatment of epilepsy, in the US market.

Under the agreement, products would be developed and submitted for approval to the USFDA. Ranbaxy Pharmaceuticals Inc would market the products under the company's label.

Zonisamide Capsules, which are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy, have total annualised sales of $170.30 million, Ranbaxy informed the Stock Exchanges.

 "Such partnerships with companies like Invagen, who have capabilities and competencies to develop bioequivalent generic product for the marketplace, are naturally beneficial to both organisations while having a positive economic impact on the US healthcare system," Atul Malhotra, president, Ranbaxy Inc said.